CA2151927A1 - Cathepsine d, protease amyloidogene dans la maladie d'alzheimer - Google Patents

Cathepsine d, protease amyloidogene dans la maladie d'alzheimer

Info

Publication number
CA2151927A1
CA2151927A1 CA002151927A CA2151927A CA2151927A1 CA 2151927 A1 CA2151927 A1 CA 2151927A1 CA 002151927 A CA002151927 A CA 002151927A CA 2151927 A CA2151927 A CA 2151927A CA 2151927 A1 CA2151927 A1 CA 2151927A1
Authority
CA
Canada
Prior art keywords
app
cathepsin
amyloid
inhibitor
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002151927A
Other languages
English (en)
Inventor
Paul Perry Tamburini
Gunter Hans Heinz Herbert Benz
Dieter Habich
Robert Norman Dreyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2151927A1 publication Critical patent/CA2151927A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478Aspartic endopeptidases (3.4.23)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81Protease inhibitors
    • G01N2333/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8142Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472Aspartic endopeptidases (3.4.23)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
CA002151927A 1992-12-16 1993-11-12 Cathepsine d, protease amyloidogene dans la maladie d'alzheimer Abandoned CA2151927A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99566092A 1992-12-16 1992-12-16
US995,660 1992-12-16

Publications (1)

Publication Number Publication Date
CA2151927A1 true CA2151927A1 (fr) 1994-06-23

Family

ID=25542079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002151927A Abandoned CA2151927A1 (fr) 1992-12-16 1993-11-12 Cathepsine d, protease amyloidogene dans la maladie d'alzheimer

Country Status (3)

Country Link
JP (1) JPH08508464A (fr)
CA (1) CA2151927A1 (fr)
WO (1) WO1994013319A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977074A (en) * 1993-10-01 1999-11-02 Merrell Pharmaceuticals, Inc. Inhibitors of β-amyloid protein production
CA2191924A1 (fr) 1995-12-05 1997-06-06 Kevin Felsenstein Derives de 5-amino-6-cyclohexyl-4-hydroxyhexanamide, inhibiteurs de la production de proteine .beta.-amyloide
EP1039883A4 (fr) * 1996-07-09 2001-09-26 Keith A Crutcher Methodes de traitement de maladies liees a l'apolipoproteine e
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
GB9815163D0 (en) * 1998-07-13 1998-09-09 Brax Genomics Ltd Compounds
ES2318902T3 (es) * 1998-09-24 2009-05-01 PHARMACIA & UPJOHN COMPANY LLC Secretasa en la enfermedad del alzheimer.
AU3194900A (en) * 1999-03-19 2000-10-09 Yamanouchi Pharmaceutical Co., Ltd. Method for screening cysteine protease inhibitor
GB0008710D0 (en) * 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
JP2008100969A (ja) * 2006-10-20 2008-05-01 Tetsuhiro Niitome 桑の葉抽出物を含むアルツハイマー病の予防または治療用の飲食物および医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650661A (en) * 1982-09-15 1987-03-17 Aktiebolaget Hassle Enzyme inhibitors
US5187153A (en) * 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US4963654A (en) * 1989-02-13 1990-10-16 Taisho Pharmaceutical Co., Ltd. Peptide serine protease inhibitor
WO1992003542A1 (fr) * 1990-08-17 1992-03-05 Boston University PROTEASE PROVOQUANT UNE DEGRADATION ANORMALE DU PRECURSEUR DE PROTEINE-β D'AMYLOIDE
DE4026614A1 (de) * 1990-08-23 1992-02-27 Bayer Ag Phosphonopyrrolidin- und piperidin-haltige pseudopeptide vom statintyp, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel gegen retroviren

Also Published As

Publication number Publication date
JPH08508464A (ja) 1996-09-10
WO1994013319A1 (fr) 1994-06-23

Similar Documents

Publication Publication Date Title
US6221645B1 (en) β-secretase antibody
US5292652A (en) Amyloidin protease and uses thereof
US7479372B2 (en) Beta-secretase substrates and uses thereof
US5942400A (en) Assays for detecting β-secretase
EP1842859B1 (fr) Anticorps monoclone spécifique de peptide A4 beta
US6325989B1 (en) Form of dipeptidylpeptidase IV (CD26) found in human serum
US5981208A (en) Diagnostic assay for Alzheimer's disease based on the proteolysis of the amyloid precursor protein
JP2003503072A (ja) 触媒的に活性な組換えメマプシンおよびその使用方法
NO320067B1 (no) In vitro fremgangsmate for registrering av prosessering av beta-amyloid forloper proteinet (betaAPP) i celler og opploselig fragment av beta-amyloid forloper protein i renset og isolert form.
US5968764A (en) Glucose transporter vesicle aminopeptidase
WO1995013084A1 (fr) Identification de la cathepsine d comme protease amyloïdogene de la maladie d'alzheimer
AU679675B2 (en) Methods for detecting beta amyloid precursor protein processing enzymes
CA2151927A1 (fr) Cathepsine d, protease amyloidogene dans la maladie d'alzheimer
US20030092629A1 (en) Inhibitors of memapsin 2 and use thereof
AU785240B2 (en) Novel bee venom polypeptides and methods of use thereof
US7189699B2 (en) Peptides for the treatment of Alzheimer's disease and other β-amyloid protein fibrillogenesis disorders
AU5726494A (en) Cathepsin d is an amyloidogenic protease in alzheimer's disease
AU7115094A (en) Cathepsin d is an amyloidogenic protease in alzheimer's disease
NZ272218A (en) Regulation of formation of beta-amyloid with a beta-amyloid precursor protease inhibitor
EP1496124A1 (fr) Inhibiteurs de mémapsine 2 et son utilisation

Legal Events

Date Code Title Description
FZDE Dead